Log In
BCIQ
Print this Print this
 

Talimogene/MK-3475

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionCombination of MK-3475 and talimogene
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I/II
Standard IndicationMelanoma
Indication DetailsTreat mid to late stage melanoma
Regulatory Designation
PartnerAmgen Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today